Earnings call transcript: Dr. Reddy’s Q4 2026 misses earnings expectations

Dr. Reddy’s Q4 FY2026 results missed expectations sharply, with EPS of $0.0616 versus $0.1255 consensus and revenue of $789.1 million versus $893.0 million, while gross margin fell 760 bps year over year to 48%. The miss was driven by a $48 million lenalidomide shelf-stock adjustment, lower lenalidomide sales, and generic price erosion, though management said base business growth remained double-digit and margins should improve above 50% in FY2027. Shares still rose 1.48% premarket as investors focused on semaglutide approvals, biosimilar progress, and guidance for continued growth and dividend payout.

Analysis

The market is treating this as a transitory reset, but the more important signal is that RDY’s earnings power is becoming increasingly “story-driven” around a handful of launch assets while the legacy generics base is still doing the heavy lifting. That creates a much more binary setup than the headline beat/miss suggests: semaglutide and abatacept are now the marginal drivers of valuation, while any slippage in approvals or launch sequencing can overwhelm otherwise healthy underlying growth. The premarket strength likely reflects investors anchoring on FY27 margin recovery, but the quarter shows how quickly product mix can erase that bridge.

The competitive dynamics are more nuanced than “generic launch = price collapse.” In semaglutide, early approval in Canada and a broader emerging-market rollout may actually support a multi-channel pricing structure for longer than consensus expects, because reimbursement, cash-pay, and partner-led markets will not clear at the same price point. That matters for NVO too: the first wave of copy entrants does not necessarily force a single global price reset, but it does compress the innovators’ ability to defend premium pricing in public channels while preserving higher net realization elsewhere.

The underappreciated risk is execution concentration. RDY is guiding to better margins largely on the assumption that semaglutide scales fast enough to offset continued U.S. generic erosion and that biologics are not delayed again; both are regulatory and operational variables with month-to-quarter latency, not immediate catalysts. If Brazil slips further or U.S. biologics timelines push out, FY27 margin expansion could look more like a FY28 story, which would leave the stock vulnerable after this relief rally.

The contrarian view is that the quarter may have marked a cyclical low in the legacy North America franchise, but the market is not yet paying for the optionality embedded in the next 12 months of launches. The stock can work if investors believe RDY can monetize semaglutide at scale before the biosimilar ramp fully capitalizes, but if that window narrows, the current rerating is fragile. The asymmetry is better in pairs than outright longs here, because the business is improving but not clean enough to deserve a stand-alone multiple expansion yet.

Key Decisions for Investors

• Long ALVOW / short RDY for 3-6 months: if semaglutide approvals and launches stay on schedule, Alvotech’s upside is more directly tied to biosimilar execution; RDY carries more near-term mix and margin noise. Use as a relative-value hedge against RDY’s launch-delay risk.
• Sell RDY downside puts into the premarket bounce, 1-2 month tenor: the stock is likely to grind rather than trend if FY27 margin evidence remains narrative-only. Attractive if implied vol has not fully repriced the approval/launch uncertainty.
• Pair long NVO / short RDY over 3-6 months: RDY’s semaglutide upside is real, but NVO retains the pricing architecture and can defend share longer in premium channels; this isolates execution risk in RDY while keeping GLP-1 demand exposure.
• Avoid chasing RDY outright long here; wait for either a pullback or a concrete launch/approval catalyst in Brazil/U.S. biosimilars. Risk/reward is asymmetric only if the market starts discounting FY28 rather than FY27.
• For multi-strategy books, consider a catalyst basket long RDY vs short a basket of higher-valuation Indian pharma names with weaker near-term launch optionality; use a 3-6 month horizon and stop if Brazil or abatacept timelines move materially right.